Ascentage Pharma Group International (AAPG)
NASDAQ: AAPG · Real-Time Price · USD
26.48
+0.28 (1.07%)
At close: Jan 23, 2026, 4:00 PM EST
26.50
+0.02 (0.08%)
After-hours: Jan 23, 2026, 6:18 PM EST
AAPG Revenue
Ascentage Pharma Group International had revenue of 116.85M CNY in the half year ending June 30, 2025, a decrease of -71.63%. This brings the company's revenue in the last twelve months to 390.60M, down -56.75% year-over-year. In the year 2024, Ascentage Pharma Group International had annual revenue of 980.65M with 341.77% growth.
Revenue (ttm)
390.60M CNY
Revenue Growth
-56.75%
P/S Ratio
44.06
Revenue / Employee
645,625 CNY
Employees
605
Market Cap
2.40B USD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 980.65M | 758.67M | 341.77% |
| Dec 31, 2023 | 221.98M | 12.27M | 5.85% |
| Dec 31, 2022 | 209.71M | 181.80M | 651.38% |
| Dec 31, 2021 | 27.91M | 15.46M | 124.18% |
| Dec 31, 2020 | 12.45M | -2.06M | -14.21% |
| Dec 31, 2019 | 14.51M | 7.71M | 113.21% |
| Dec 31, 2018 | 6.81M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sarepta Therapeutics | 2.41B |
| Telix Pharmaceuticals | 664.23M |
| Ultragenyx Pharmaceutical | 630.60M |
| Travere Therapeutics | 435.83M |
| Galapagos NV | 336.64M |
| Wave Life Sciences | 109.23M |
| Ocular Therapeutix | 55.78M |
| Recursion Pharmaceuticals | 43.69M |
AAPG News
- 9 days ago - Ascentage Pharma Group International (AAPG) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 10 days ago - Ascentage Pharma Outlined its Global Innovation Strategy During Presentation at 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 6 weeks ago - ASH 2025 | Ascentage Pharma Presents Four-Year Follow-Up Data from Registrational Phase II Study of Olverembatinib, Reaffirming Differentiated Long-Term Efficacy and Safety in TKI-Resistant/Intolerant CML-CP - GlobeNewsWire
- 6 weeks ago - ASH 2025 | Ascentage Pharma Presents First Dataset from Phase III POLARIS-1 Study of Olverembatinib in Newly Diagnosed Ph+ ALL Shows a Best MRD-Negativity CR Rate Exceeding 60% - GlobeNewsWire
- 6 weeks ago - ASH 2025 | Updated Data for Ascentage Pharma‘s Olverembatinib in Second-Line CML-CP Showing Encouraging Potential for Early-Line Treatment - GlobeNewsWire
- 6 weeks ago - ASH 2025 | Ascentage Pharma Presents Encouraging Data from Phase Ib/II Study of Bcl-2 Inhibitor Lisaftoclax in Venetoclax–Exposed Patients with Myeloid Malignances - GlobeNewsWire
- 7 weeks ago - Ascentage Pharma Presents Pivotal China Registrational Study Data for Lisaftoclax in Oral Report at 2025 American Society of Hematology (ASH) Annual Meeting - GlobeNewsWire
- 7 weeks ago - Ascentage Pharma Announces Global Registrational Phase III Study of Olverembatinib in First-Line Treatment of Ph+ ALL Cleared by US FDA and EMA - GlobeNewsWire